Our Pricing

10mg Weight Loss Injections Online UK

Published on: June 03, 2026

Accessing 10mg weight loss injections online UK has become straightforward through regulated pharmacy services. At Cured Pharmacy, our UK-registered clinical team provides free consultations for prescription weight loss injections including Mounjaro, Wegovy, and Saxenda, with transparent pricing and discreet next-day delivery across the UK.

Understanding 10mg Weight Loss Injections and Dosing

The term '10mg' typically refers to mid-to-high maintenance doses used in GLP-1 and dual GIP/GLP-1 receptor agonist therapies. Mounjaro (tirzepatide), for instance, offers doses up to 15mg weekly, whilst Wegovy (semaglutide) reaches a maintenance dose of 2.4mg weekly [1]. These medications work by mimicking natural incretin hormones that regulate appetite, slow gastric emptying, and improve insulin sensitivity.

Clinical trials demonstrate substantial efficacy at therapeutic doses. In the SURMOUNT-1 trial, participants receiving tirzepatide 15mg achieved an average body weight reduction of 20.9% over 72 weeks, compared to 3.1% with placebo [1]. Similarly, the STEP-1 trial showed semaglutide 2.4mg produced an average 14.9% weight reduction over 68 weeks [2].

Dosing always follows a gradual escalation protocol to minimise gastrointestinal side effects. Your UK prescriber will start you on a lower dose and increase incrementally every 4 weeks until you reach your optimal maintenance dose, which may range from 5mg to 15mg for tirzepatide or up to 2.4mg for semaglutide, depending on tolerance and clinical response.

How GLP-1 and Dual GIP/GLP-1 Injections Work

GLP-1 (glucagon-like peptide-1) receptor agonists like semaglutide and liraglutide activate a single hormone pathway that reduces appetite and slows digestion. These medications have been used in diabetes management for over a decade before receiving MHRA approval for weight management in adults with obesity or overweight with weight-related complications [2][3].

Tirzepatide represents a newer class as the first dual GIP/GLP-1 receptor agonist licensed in the UK. By activating both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, it produces enhanced metabolic effects. Head-to-head trials suggest tirzepatide may produce greater weight loss compared to semaglutide, though individual responses vary [1][4].

Both medication types require subcutaneous injection, typically into the abdomen, thigh, or upper arm. Modern pre-filled pens make self-administration straightforward, with most patients reporting minimal discomfort. Injections are administered once weekly for both tirzepatide and semaglutide, or once daily for liraglutide (Saxenda).

Mechanism of Action in Weight Management

These injections work through multiple pathways: they reduce hunger signals in the brain, slow stomach emptying to prolong fullness, and improve insulin sensitivity. Clinical observations show patients typically experience reduced cravings and smaller portion sizes naturally, rather than through forced restriction [2][3].

The medications are most effective when combined with dietary modifications and increased physical activity. NICE guidelines recommend their use as part of a comprehensive weight management programme that includes behavioural support and lifestyle interventions [5].

Comparing Weight Loss Injection Options Available in the UK

Three main injectable options are currently available through UK pharmacies: Mounjaro (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide). Each has distinct characteristics regarding dosing frequency, efficacy data, and side effect profiles.

Mounjaro offers the highest average weight loss in clinical trials but requires careful dose escalation. Wegovy provides once-weekly convenience with robust trial data across diverse populations. Saxenda, whilst requiring daily injections, has the longest real-world safety data and may suit patients who prefer more frequent dosing control [1][2][3].

Your UK prescriber will consider your medical history, previous weight loss attempts, current medications, and personal preferences when recommending a specific treatment. Factors such as cardiovascular risk, diabetes status, and gastrointestinal tolerance all influence the most appropriate choice.

Efficacy Comparison Across Clinical Trials

Direct comparison trials provide valuable guidance. The SURPASS-2 trial directly compared tirzepatide against semaglutide 1mg in type 2 diabetes patients, showing superior weight loss with tirzepatide across all dose levels [4]. However, semaglutide 2.4mg (the Wegovy dose) has not been directly compared to tirzepatide in obesity trials.

Real-world effectiveness may differ from trial conditions. Individual response varies considerably, and some patients achieve excellent results with any of these medications whilst others may require dose adjustments or treatment switches [5].

The Online Consultation Process at Cured Pharmacy

Our online consultation takes under 3 minutes to complete and asks about your medical history, current medications, weight loss goals, and any contraindications. This information is reviewed by a UK-registered prescriber—either a GP or an independent prescriber working under the supervision of our superintendent pharmacist, Tarun Kumar (GPhC 2233073).

The prescriber assesses your suitability based on MHRA licensing criteria and NICE guidelines. Weight loss injections are typically prescribed for adults with a BMI of 30 or above, or 27 or above with weight-related health conditions such as hypertension, type 2 diabetes, or sleep apnoea [5]. Your prescriber may request additional information or suggest alternative treatments if injectable medications are not appropriate for your circumstances.

Once approved, your prescription is dispensed from our UK-registered pharmacy (GPhC 9012511) and dispatched in discreet packaging. We offer next-day delivery across the UK, and all medications are genuine UK-licensed products sourced through regulated supply chains. You'll receive clear instructions on injection technique, dose escalation schedules, and when to contact us with concerns.

Pricing Transparency for Weight Loss Injections

At Cured Pharmacy, we display prices before you complete your consultation, eliminating unwelcome surprises. Our pricing structure reflects the genuine UK supply costs and includes the clinical consultation, prescription, and delivery.

Weight loss injection costs vary based on the specific medication and dose prescribed. Prices reflect the monthly supply needed for your prescribed regimen. We guarantee the lowest prices in the UK for genuine licensed medications and will match any verified lower price from another UK-registered pharmacy.

Unlike some services that advertise low entry prices but charge significantly more for effective doses, our pricing is transparent across all dose levels. The price you see during consultation is the price you pay, with no hidden fees or mandatory subscription lock-ins beyond the initial treatment period.

Understanding Treatment Costs Over Time

Weight loss injection therapy typically requires 6-12 months of continuous treatment to achieve optimal results, with some patients continuing longer-term for weight maintenance. Your total treatment cost will depend on your prescribed dose, treatment duration, and individual response.

Most patients begin seeing results within 4-8 weeks, with maximum weight loss typically achieved between 60-72 weeks of treatment [1][2]. Discussing realistic timelines and costs with your prescriber during consultation helps set appropriate expectations.

Safety Considerations and Potential Side Effects

The most common side effects of GLP-1 and dual GIP/GLP-1 injections are gastrointestinal: nausea, diarrhoea, constipation, and abdominal discomfort. These effects typically occur during dose escalation and diminish over time as your body adjusts [1][2][3]. Starting at low doses and increasing gradually minimises these symptoms.

More serious but rare side effects include pancreatitis, gallbladder disease, and allergic reactions. Clinical trials have monitored for thyroid tumours following animal studies, though no causal link has been established in humans. Nevertheless, these medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1][2].

Your prescriber will review your complete medical history to identify contraindications. These medications should not be used during pregnancy or breastfeeding, and caution is required in patients with severe gastrointestinal disease, diabetic retinopathy, or renal impairment. Regular monitoring through follow-up consultations ensures any concerns are addressed promptly.

If you experience severe abdominal pain, persistent vomiting, or signs of allergic reaction, discontinue the medication and seek immediate medical attention. Our pharmacy team is available on (+44) 116 4646009 during business hours for non-emergency clinical questions.

Drug Interactions and Contraindications

Weight loss injections can affect the absorption of oral medications due to delayed gastric emptying. This is particularly relevant for medications requiring rapid absorption or those with narrow therapeutic windows. Your prescriber will review all current medications during consultation [3][5].

Patients taking insulin or sulfonylureas for diabetes may require dose adjustments to prevent hypoglycaemia. Women of childbearing age should use reliable contraception, as weight loss itself can affect fertility and these medications are not recommended during pregnancy.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-218. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence, diet, and physical activity.